RESMED INC (RMD)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:

RMD - RESMED INC
FNArena Sector :
Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.54
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS
FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.54
ResMed is the global market leader in providing devices for the treatment of sleep apnoea and chronic pulmonary disease. Formed in Australia in 1989 the company listed on the ASX in 1999 and is also listed on the NYSE. ResMed's head office is in San Diego, California.
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$38.69
06 Feb |
OPEN $38.88 |
HIGH $38.88 |
2,283,396 LOW $38.49 |
TARGET | |||||
|
OTHER COMPANIES IN THE SAME SECTOR | |||
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . SOM . TRJ . UBI . VTI . |
FNARENA'S MARKET CONSENSUS FORECASTS
Title | FY25 Forecast |
FY26 Forecast |
---|---|---|
EPS (cps) | 145.0 | xxx |
DPS (cps) | 33.2 | xxx |
EPS Growth | N/A | xxx |
DPS Growth | N/A | xxx |
PE Ratio | 26.0 | xxx |
Dividend Yield | 0.9% | xxx |
Div Pay Ratio(%) | 22.9% | xxx |
All estimates have been converted into AUD by FNArena at present FX values.
Last ex-div: 06/11 - (franking ex-di
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | xxx | 106.0 |
DPS All | xxx | xxx | xxx | xxx | xxx | 29.6 |
Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 7,150.0 M |
Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 495.8 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | 2,138.4 M |
Net Profit Margin | xxx | xxx | xxx | xxx | xxx | 21.79 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | 23.10 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | 18.26 % |
Return on Assets | xxx | xxx | xxx | xxx | xxx | 15.25 % |
Return on Equity | xxx | xxx | xxx | xxx | xxx | 23.10 % |
Return on Total Capital | xxx | xxx | xxx | xxx | xxx | 24.60 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | 1,555.8 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 53 M |
Long Term Debt | xxx | xxx | xxx | xxx | xxx | 1,256 M |
Total Debt | xxx | xxx | xxx | xxx | xxx | 1,309 M |
Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | 4,256 M |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 357 M |
Price To Book Value | xxx | xxx | xxx | xxx | xxx | 5.87 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | xxx | 175.3 M |
Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 2.45 % |
Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 3,169 M |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 1,869 M |
Research & Development | xxx | xxx | xxx | xxx | xxx | 469 M |
Investments - Total | xxx | xxx | xxx | xxx | xxx | 227 M |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
EXTRA COVERAGE
Display All Commentary
No. Of Recommendations
Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.
RMD STOCK CHART

FNArena News on RMD
1 |
In Case You Missed It – BC Extra Upgrades & Downgrades – 07-02-25Feb 07 2025 - Weekly Reports |
2 |
ESG Focus: Top ASX Companies, Superbugs & HydrogenFeb 07 2025 - ESG Focus |
3 |
Rudi’s View: AGL Energy, Bega Cheese, BRG, Harvey Norman, Imdex & SuperloopFeb 06 2025 - Rudi's View |
4 |
FNArena Corporate Results Monitor – 05-02-2025Feb 05 2025 - Australia |
5 |
Rudi’s View: Earnings Optimism On The RiseFeb 05 2025 - Rudi's View |
Latest Medical Equipment & Devices News
1 |
ESG Focus: Top ASX Companies, Superbugs & HydrogenFeb 07 2025 - ESG Focus |
2 |
ResMed Shakes Off GLP-1 ScareFeb 04 2025 - Australia |
3 |
ResMed: Another Positive Quarterly Surprise?Jan 30 2025 - Australia |
4 |
The Trend Remains Pro Medicus’ FriendJan 16 2025 - Technicals |
5 |
Diagnostic Imaging Radiates OpportunityDec 18 2024 - Small Caps |
6 |
ResMed’s Bounce-Back CompleteOct 29 2024 - Australia |
7 |
Dr Boreham’s Crucible: Pro MedicusSep 04 2024 - Australia |
8 |
Pro Medicus: Don’t Stop Me NowAug 20 2024 - Technicals |
9 |
Dr Boreham’s Crucible: BlinklabMay 20 2024 - Small Caps |
10 |
ResMed Silences The DoubtersApr 29 2024 - Australia |